Fiasp Purple Book BLA 208751

BLA number
208751
Proprietary names
Fiasp
Proper names
insulin aspart
Applicant
Novo Nordisk Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Fiaspinsulin aspart351(a)1000UNITS/10ML (100UNITS/ML)InjectionIntravenous, SubcutaneousMulti-Dose VialRxLicensed2017-09-29
002Fiaspinsulin aspart351(a)300UNITS/3ML (100UNITS/ML)InjectionSubcutaneousAutoinjectorRxLicensed2017-09-29
003Fiaspinsulin aspart351(a)300UNITS/3ML (100UNITS/ML)InjectionSubcutaneousMulti-Dose CartridgeRxLicensed2018-09-24
004Fiaspinsulin aspart351(a)160UNITS/1.6ML (100UNITS/ML)InjectionSubcutaneousMulti-Dose CartridgeRxLicensed2023-06-21

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-06-01N004Fiasp351(a)RxNovo Nordisk Inc.
2020-05-01R001Fiasp351(a)RxNovo Nordisk Inc.
2020-05-01R002Fiasp351(a)RxNovo Nordisk Inc.
2020-05-01R003Fiasp351(a)RxNovo Nordisk Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2023-06-01004Fiasp351(a)RxLicensed2023-06-21
2020-05-01001Fiasp351(a)RxLicensed2017-09-29
2020-05-01002Fiasp351(a)RxLicensed2017-09-29
2020-05-01003Fiasp351(a)RxLicensed2018-09-24